Ideal according to consensus criteria, n (%) | 26 (57.8) |
Prostate volume, median (IQR) | 35 (27–46) |
Location of treatment (combined treatment fields for n = 5 with 2 HIFU treatments) | |
 Hemi-gland unilateral |  |
 Hemi-gland with extension across midline or into SV | 16 |
 Hemi-gland anterior | 7 |
 Hemi-gland posterior | 1 |
 Quadrant (e.g. unilateral posterior) | 1 |
 Focal ablation (eg posterior right basal segment) | 13 |
 Subtotal (extended hemi-ablation, sparing lateral aspect of contralateral side) | 6 |
1 | |
Number of HIFU treatments | |
 1 | 37 |
 2 | 8 |
Known ‘insignificant’ cancer left untreated at HIFU | |
 Yes | 21 (47.7) |
 No | 23 (52.3) |
Type of biopsy pre-HIFU: | |
 TTMB TP 5 mm Mapping + MRI-Targeted (if targets) | 24 (53.3) |
 12–20 core TRUS + MR-targeted (if targets) | 17 (37.8) |
 Targeted alone | 3 (6.7) |
 Not documented | 1 (2.2) |